OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Clinical implication of low estrogen receptor (ER-low) expression in breast cancer
Tomás Reinert, Fanny Cascelli, Cristiano Augusto Andrade de Resende, et al.
Frontiers in Endocrinology (2022) Vol. 13
Open Access | Times Cited: 29
Tomás Reinert, Fanny Cascelli, Cristiano Augusto Andrade de Resende, et al.
Frontiers in Endocrinology (2022) Vol. 13
Open Access | Times Cited: 29
Showing 1-25 of 29 citing articles:
“Diagnostic and Prognostic Biomarkers of Luminal Breast Cancer: Where are We Now?”
A Holler, Bich Doan Nguyen-Sträuli, Heike Frauchiger-Heuer, et al.
Breast Cancer Targets and Therapy (2023) Vol. Volume 15, pp. 525-540
Open Access | Times Cited: 14
A Holler, Bich Doan Nguyen-Sträuli, Heike Frauchiger-Heuer, et al.
Breast Cancer Targets and Therapy (2023) Vol. Volume 15, pp. 525-540
Open Access | Times Cited: 14
Bisphenol-A in Drinking Water Accelerates Mammary Cancerogenesis and Favors an Immunosuppressive Tumor Microenvironment in BALB–neuT Mice
Chiara Focaccetti, Daniela Nardozi, Monica Benvenuto, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 11, pp. 6259-6259
Open Access | Times Cited: 5
Chiara Focaccetti, Daniela Nardozi, Monica Benvenuto, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 11, pp. 6259-6259
Open Access | Times Cited: 5
Breast Cancer-the-State-of-the Art in the World and Islamic Development Banks Members Countries (IsDB-MCs)
Ahmed A. M. Elnour
(2025), pp. 169-213
Closed Access
Ahmed A. M. Elnour
(2025), pp. 169-213
Closed Access
Prognostic Impact of ER-Staining Patterns and Heterogeneity of ER positive HER2 negative Breast Cancer
Yoshiko Akita, Ravi Velaga, Madoka Iwase, et al.
Research Square (Research Square) (2025)
Closed Access
Yoshiko Akita, Ravi Velaga, Madoka Iwase, et al.
Research Square (Research Square) (2025)
Closed Access
Navigating practical challenges in immunotherapy for metastatic triple negative breast cancer
Luca Licata, Maria Vittoria Dieci, Carmine De Angelis, et al.
Cancer Treatment Reviews (2024) Vol. 128, pp. 102762-102762
Open Access | Times Cited: 4
Luca Licata, Maria Vittoria Dieci, Carmine De Angelis, et al.
Cancer Treatment Reviews (2024) Vol. 128, pp. 102762-102762
Open Access | Times Cited: 4
Effect of PR status on the prognosis of advanced ER-high HER2-negative breast cancer patients receiving CDK4/6 inhibitor combined with endocrine as first-line therapy
Lin Jia, Junning Peng, Nan Sun, et al.
BMC Cancer (2024) Vol. 24, Iss. 1
Open Access | Times Cited: 4
Lin Jia, Junning Peng, Nan Sun, et al.
BMC Cancer (2024) Vol. 24, Iss. 1
Open Access | Times Cited: 4
Pathologic complete response rates of patients with ER-low/HER2-negative breast cancer treated with neoadjuvant pembrolizumab plus chemotherapy in the neo-real study
Renata Colombo Bonadio, Monique Celeste Tavares, Flávia Cavalcanti Balint, et al.
Breast Cancer Research and Treatment (2025)
Closed Access
Renata Colombo Bonadio, Monique Celeste Tavares, Flávia Cavalcanti Balint, et al.
Breast Cancer Research and Treatment (2025)
Closed Access
Prognosis, clinicopathological characteristics, and treatment patterns of patients with ER-intermediate-positive breast cancer undergoing long-term follow-up
Naoya Matsumoto, Yumi Wanifuchi‐Endo, Takashi Fujita, et al.
ESMO Open (2025) Vol. 10, Iss. 4, pp. 104508-104508
Open Access
Naoya Matsumoto, Yumi Wanifuchi‐Endo, Takashi Fujita, et al.
ESMO Open (2025) Vol. 10, Iss. 4, pp. 104508-104508
Open Access
Estrogen-Receptor-Low-Positive Breast Cancer: Pathological and Clinical Perspectives
Christina Panagiotis Malainou, Nikolina Stachika, Aikaterini Konstantina Damianou, et al.
Current Oncology (2023) Vol. 30, Iss. 11, pp. 9734-9745
Open Access | Times Cited: 7
Christina Panagiotis Malainou, Nikolina Stachika, Aikaterini Konstantina Damianou, et al.
Current Oncology (2023) Vol. 30, Iss. 11, pp. 9734-9745
Open Access | Times Cited: 7
Protein biomarkers for diagnosis of breast cancer
Emeka Iweala, Doris Nnenna Amuji, Faith Chinasaokwu Nnaji
Scientific African (2024) Vol. 25, pp. e02308-e02308
Open Access | Times Cited: 2
Emeka Iweala, Doris Nnenna Amuji, Faith Chinasaokwu Nnaji
Scientific African (2024) Vol. 25, pp. e02308-e02308
Open Access | Times Cited: 2
The “lows”: update on ER-low and HER2-low breast cancer
Nicola Fusco, G. Viale
The Breast (2024) Vol. 78, pp. 103831-103831
Open Access | Times Cited: 2
Nicola Fusco, G. Viale
The Breast (2024) Vol. 78, pp. 103831-103831
Open Access | Times Cited: 2
Advances in Early Breast Cancer Risk Profiling: From Histopathology to Molecular Technologies
Carlo Pescia, Elena Guerini‐Rocco, Giuseppe Viale, et al.
Cancers (2023) Vol. 15, Iss. 22, pp. 5430-5430
Open Access | Times Cited: 6
Carlo Pescia, Elena Guerini‐Rocco, Giuseppe Viale, et al.
Cancers (2023) Vol. 15, Iss. 22, pp. 5430-5430
Open Access | Times Cited: 6
The most likely but largely ignored triggering factor for breast (or all) cancer invasion
Yan‐Gao Man, Ciaran Mannion, Alexander Stojadinovic, et al.
Journal of Cancer (2023) Vol. 14, Iss. 4, pp. 573-590
Open Access | Times Cited: 5
Yan‐Gao Man, Ciaran Mannion, Alexander Stojadinovic, et al.
Journal of Cancer (2023) Vol. 14, Iss. 4, pp. 573-590
Open Access | Times Cited: 5
A novel bystander effect in tamoxifen treatment: PPIB derived from ER+ cells attenuates ER− cells via endoplasmic reticulum stress-induced apoptosis
Ting-Lin Yang, Wenhui Li, Jun Zhou, et al.
Cell Death and Disease (2024) Vol. 15, Iss. 2
Open Access | Times Cited: 1
Ting-Lin Yang, Wenhui Li, Jun Zhou, et al.
Cell Death and Disease (2024) Vol. 15, Iss. 2
Open Access | Times Cited: 1
CORRELATION OF TUMOR MARKERS HER2 NEU ER PR AND KI 67 IN BREAST CANCER PATIENTS
MN RASHID, NU HUDA, Lubna Riaz, et al.
Biological and Clinical Sciences Research Journal (2024) Vol. 2024, Iss. 1, pp. 793-793
Open Access | Times Cited: 1
MN RASHID, NU HUDA, Lubna Riaz, et al.
Biological and Clinical Sciences Research Journal (2024) Vol. 2024, Iss. 1, pp. 793-793
Open Access | Times Cited: 1
MRI features of breast cancer immunophenotypes with a focus on luminal estrogen receptor low positive invasive carcinomas
Carla Chizuru Tajima, Fernanda Pini Sapata Gonçalves Arruda, Victor Chequer Mineli, et al.
Scientific Reports (2024) Vol. 14, Iss. 1
Open Access | Times Cited: 1
Carla Chizuru Tajima, Fernanda Pini Sapata Gonçalves Arruda, Victor Chequer Mineli, et al.
Scientific Reports (2024) Vol. 14, Iss. 1
Open Access | Times Cited: 1
Therapeutic implications of the interplay between interferons and ER in breast cancer
Nataša Todorović‐Raković, Jonathan R. Whitfield
Cytokine & Growth Factor Reviews (2024) Vol. 75, pp. 119-125
Closed Access
Nataša Todorović‐Raković, Jonathan R. Whitfield
Cytokine & Growth Factor Reviews (2024) Vol. 75, pp. 119-125
Closed Access
Is Oncotype DX testing informative for breast cancers with low ER expression? A retrospective review from a biomarker testing referral center
John Loggie, Penelope J. Barnes, Michael D. Carter, et al.
The Breast (2024) Vol. 75, pp. 103715-103715
Open Access
John Loggie, Penelope J. Barnes, Michael D. Carter, et al.
The Breast (2024) Vol. 75, pp. 103715-103715
Open Access
The prevalence of ER-low-positive breast cancer and its relation to tumor characteristics in Syria
Remal Abdulaziz Asaad, Hla Sudan, Bailasan Hasan, et al.
Forum of Clinical Oncology (2024)
Open Access
Remal Abdulaziz Asaad, Hla Sudan, Bailasan Hasan, et al.
Forum of Clinical Oncology (2024)
Open Access
Canassist Breast Provides Additional Insightful Prognostic Information in Clinically Low-Risk and High-Risk Patients with Hr+/Her2- Early-Stage Breast Cancer
Tejal Deepak Durgekar, Susmita Ghosh, Badada Ananthamurthy Savitha, et al.
(2024)
Closed Access
Tejal Deepak Durgekar, Susmita Ghosh, Badada Ananthamurthy Savitha, et al.
(2024)
Closed Access
Genes Related to Motility in an Ionizing Radiation and Estrogen Breast Cancer Model
Tania Köning, Gloria M. Calaf
Biology (2024) Vol. 13, Iss. 11, pp. 849-849
Open Access
Tania Köning, Gloria M. Calaf
Biology (2024) Vol. 13, Iss. 11, pp. 849-849
Open Access
Retrospective evaluation of the efficacy of CDK4/6 inhibitors compared to ER and PR levels in hormone receptor positive HER2 negative metastatic breast cancer patient
Esma Uguztemur, Derya Kıvrak Salim, Banu Öztürk
Research Square (Research Square) (2024)
Closed Access
Esma Uguztemur, Derya Kıvrak Salim, Banu Öztürk
Research Square (Research Square) (2024)
Closed Access
Rewriting nuclear epigenetic scripts in mitochondrial diseases as a strategy for heteroplasmy control
Marı́a José Pérez-Fabello, Rocío B. Colombo, Sebastián Real, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2024)
Closed Access
Marı́a José Pérez-Fabello, Rocío B. Colombo, Sebastián Real, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2024)
Closed Access
Tonsil tissue control is ideal for monitoring estrogen receptor immunohistochemical staining
Chia-Pin Chang, Jen‐Fan Hang, Chih‐Jung Chen, et al.
Journal of the Chinese Medical Association (2023)
Open Access | Times Cited: 1
Chia-Pin Chang, Jen‐Fan Hang, Chih‐Jung Chen, et al.
Journal of the Chinese Medical Association (2023)
Open Access | Times Cited: 1
Unexpectedly large myoepithelioma-like tumor of the vulvar region with two local recurrences: A rare case report and review of the literature
Soheila Aminimoghaddam, Soheila Sarmadi, Mahdis Kashian, et al.
Gynecologic Oncology Reports (2023) Vol. 50, pp. 101300-101300
Open Access | Times Cited: 1
Soheila Aminimoghaddam, Soheila Sarmadi, Mahdis Kashian, et al.
Gynecologic Oncology Reports (2023) Vol. 50, pp. 101300-101300
Open Access | Times Cited: 1
